Treats schizophrenia. ANDA 208045, held by Aurobindo Pharma Ltd. Lurasidone Hydrochloride.
As of Nov 16, 2026, ANDA 208045 (Lurasidone Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 10, 2023, with 1 approved supplement and 0 published complete response letters.
Lurasidone hydrochloride tablets are indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia. Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression). Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 10, 2023 | Original application | Approved | None posted |
| Lurasidone Hydrochloride20MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride40MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride60MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride80MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride120MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| May 15, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 10, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters